The Use of Direct Oral Anticoagulants for Prevention of Stroke and Systemic Embolic Events in East Asian Patients with Nonvalvular Atrial Fibrillation
作者机构：Department of CardiologyBeijing AnZhen HospitalCapital Medical UniversityBeijingChina
出 版 物：《Cardiovascular Innovations and Applications》 (心血管创新与应用（英文）)
年 卷 期：2018年第3卷第B7期
页 面：215-226页
学科分类：10[医学]
主 题：anticoagulant direct oral anticoagulant East Asia stroke
摘 要：As patients in East Asia age,the prevalence of age-related and chronic disease,including nonvalvular atrial fibrillation,may *** warfarin has been the primary choice of anticoagulant for the prevention of stroke and systemic embolic events,the use of direct oral anticoagulants(DOACs)is *** do not require monitoring of the international normalized ratio to determine the optimal dose,and have a lower potential for food and drug interactions,improved benefi t-risk profiles,and a quicker onset and offset of action relative to *** pivotal phase 3 trials for each of the DOACs– dabigatran,rivaroxaban,apixaban,and edoxaban– included at least some East Asian ***,several clinical trials were conducted specifically for East Asian *** review discusses patterns and predictors of anticoagulant use in East Asian patients with nonvalvular atrial fibrillation,summarizes current guideline recommendations for East Asian patients,details the primary results demonstrating the safety and efficacy of DOACs in East Asian patients relative to non– East Asian patients,provides real-world data supporting the phase 3 testing results,and addresses the clinical profile of DOACs in East Asian populations,including patients at high risk of stroke.
维普期刊数据库